Pharma News

In a significant development for the treatment of non-small cell lung cancer (NSCLC), Bristol Myers Squibb (BMS) has announced a major achievement in their study of KRAS inhibitors.

Harbour BioMed, a leading biopharmaceutical company, has announced its financial performance for the year 2023. The company achieved a significant milestone by realizing its first-ever annual financial profit.

This article provides a comprehensive overview of the latest updates in the field, highlighting the upcoming batch of procurements and the anticipated price reductions for high-value orthopedic and ophthalmic consumables.

In a recent development, two pharmaceutical giants, State Pharmaceutical Holdings (国药控股) and China Resources Pharmaceutical Group (华润医药), have unveiled their latest financial performance for the year 2023.

Varnotech Biopharm, a leading innovative biotech company focused on vaccine research and development, has recently announced the successful completion of its Series B funding round, raising a total of ¥600 million.

Astellas announced the approval and market launch of their Claudin18.2 antibody, Zolbetuximab (Vyloy), for the treatment of advanced gastric cancer in Japan.

NMPA has accepted the market application for a new indication of Saovitinib, a selective MET inhibitor, for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) patients with MET exon 14 skipping mutations.

In a recent development, several CEOs of multinational medical device companies visited China, indicating a positive outlook for the country's healthcare industry.

In a remarkable development, the CEO of Eli Lilly and Company, David Ricks, has witnessed a substantial increase in his annual salary, soaring to an impressive $26.6 million.

Hansoh Pharmaceutical, a renowned pharmaceutical company, has recently announced its remarkable performance for the year 2023.

Mabwell Biotech, a leading pharmaceutical company, has recently made significant strides in expanding its presence in South Asia and Africa.

In the world of innovative pharmaceuticals, pausing doesn't equate to failure; it signifies wisdom. In this high-stakes domain, taking the time to reflect and reassess can be wiser than stubbornly persisting.

Fosun Pharma, a leading pharmaceutical company, has reported remarkable financial results for the year 2023. With a strong focus on innovation and global expansion, Fosun Pharma has successfully solidified its position in the healthcare industry.

AbbieVie, a prominent player in the field of Antibody-Drug Conjugates (ADCs), has finally proven itself by successfully overcoming its challenges.

In the realm of pharmaceutical innovation, a new wave of companies is emerging, demonstrating remarkable profitability and groundbreaking advancements.

In a stunning display of financial prowess, WuXi Biologics, a leading global contract research, development, and manufacturing organization (CRDMO) for biopharmaceuticals, has announced its exceptional performance in the year 2023.

This time, it is Japanese company Sosei Group Corporation that has announced the regaining of full ownership of HTL0027477 (formerly GSK4381406) from GlaxoSmithKline (GSK), marking GSK's official exit from the IBD field.

In a groundbreaking agreement, AriBio has announced the acquisition of exclusive marketing rights for AR1001, a potential treatment for early-stage Alzheimer's disease, in China.

In a significant milestone for the pharmaceutical industry, Evive Biotech has achieved a major breakthrough with its innovative biopharmaceutical product, "Aibei Gesiting α Injection."

In the realm of ADC (Antibody-Drug Conjugate) development, a groundbreaking achievement has taken place, raising the question of whether AbbVie is about to change its destiny.